Homologous Recombination Deficiency and PARP Inhibition in Ovarian Cancer

As part of our coverage of the 2017 ASCO Annual Meeting, we discuss homologous recombination deficiency in ovarian cancer and PARP inhibitors. (Source: CancerNetwork)

from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2rxy5N2
via IFTTT